Company's test rated as the top performer in China National CDC
HALIFAX, April 4 /CNW/ - MedMira Inc., ("MedMira") (TSXV: MIR) (NASDAQ:
MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, today announced that the Company's strategic partner in
China, Triplex International Biosciences Co., Ltd. (Triplex), has
placed an initial order for 400,000 MedMira rapid HIV tests.
This order follows the completion of a critical evaluation recently
completed by the China National Center for Disease Control (China CDC)
for all the imported and domestic rapid HIV tests. The evaluation
looked at 12 of the leading rapid HIV tests available in China and
ranked performance in both sensitivity and specificity using selective
critical specimen panels. The MedMira rapid HIV test ranked number one
out of the 12 tests evaluated in the study. These evaluation results
are a key marketing tool as Triplex moves forward on sales
opportunities in the outreach clinics and hospital laboratory vertical
markets in the high growth rapid diagnostics market within China's
restructured healthcare system.
This is the first sizeable order from Triplex since they began market
development activities for MedMira in China. MedMira has begun the
production of this initial order to supply to Triplex during this
expansion phase of its business development initiatives.
"We are pleased to see our test continues to perform as the top
performer among all the available rapid tests in China and excited
about this initial order. This marks the beginning of our re-emergence
in the new China healthcare market. For the past several years China's
healthcare system has been undergoing significant restructuring. As the
new health system is rolling out across China we are very well
positioned with a strong partner in Triplex, access to the market, and
a world class rapid HIV test," said Hermes Chan, CEO, MedMira. "The
Triplex business development team has been working on various market
development initiatives in China in parallel with the health system
reforms. Building on the extremely positive results of this evaluation
and subsequent top level positioning of our product, MedMira and
Triplex joint business development team can fully capitalize on near
term sales opportunities in China."
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
infectious diseases in minutes. MedMira diagnostics are sold under the
Reveal®, MiraWell®, Multiplo™, and Miriad brands in global markets.
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MEDMIRA INC.
For further information:
MedMira Contact: Andrea Young